USANA Health Sciences (NYSE:USNA) Given New $36.00 Price Target at DA Davidson

USANA Health Sciences (NYSE:USNA) had its price target lowered by DA Davidson from $38.00 to $36.00 in a research note published on Thursday morning,Benzinga reports. The firm currently has a neutral rating on the stock. DA Davidson also issued estimates for USANA Health Sciences’ Q1 2025 earnings at $0.83 EPS, FY2025 earnings at $2.57 EPS and FY2026 earnings at $2.68 EPS.

Several other research analysts have also issued reports on USNA. Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th.

USANA Health Sciences Stock Down 14.0 %

NYSE USNA opened at $28.57 on Thursday. USANA Health Sciences has a twelve month low of $27.71 and a twelve month high of $50.32. The stock has a market cap of $544.54 million, a P/E ratio of 10.10, a PEG ratio of 0.93 and a beta of 0.87. The company’s 50-day simple moving average is $33.50 and its 200 day simple moving average is $36.56.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. Research analysts anticipate that USANA Health Sciences will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On USANA Health Sciences

A number of large investors have recently bought and sold shares of the business. R Squared Ltd bought a new position in USANA Health Sciences in the 4th quarter valued at $28,000. Safe Harbor Fiduciary LLC acquired a new stake in shares of USANA Health Sciences in the third quarter valued at $30,000. KBC Group NV raised its holdings in shares of USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of USANA Health Sciences in the fourth quarter valued at about $83,000. Finally, Quantbot Technologies LP acquired a new position in USANA Health Sciences during the 4th quarter worth about $132,000. 54.25% of the stock is currently owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.